For Non-Small Cell Lung Cancer, Nintedanib Improves Overall Survival Without Reducing Quality of Life
the Cancer Therapy Advisor take:
According to a new analysis published in the European Journal of Cancer, researchers have found that second-line nintedanib plus docetaxel for the treatment of patients with advanced non-small cell lung cancer (NSCLC) improves overall survival without decreasing quality of life.
In the double-blind, placebo-controlled, phase 3 LUME-Lung 1 study, researchers found that the combination of nintedanib with docetaxel significantly improved overall survival when used as second-line treatment for patients with advanced NSCLC and adenocarcinoma histology.
Now, researchers assessed whether the combination therapy affected patient-reported outcomes for symptoms and health-related quality of life. Patients were asked about their symptoms at screening, on the first day of each cycle, at the end of chemotherapy, and at the first follow-up appointment.
Results showed that there was no significant difference in time to deterioration of quality of life or lung cancer-specific symptoms, such as cough, dyspena, and pain, between both arms.
The difference was similar for both the overall population and those with adenocarcinoma. However, the time to deterioration of certain gastrointestinal symptoms was shorter in the nintedanib arm compared with the placebo arm. There was also no significant difference in the EuroQol disease-generic questionnaire between the two treatment arms.
Nintedanib plus docetaxel for the treatment of advanced NSCLC improves overall survival without decreasing quality of life.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Affordable Care Act Linked to Lower Rates of Cancer Diagnosis Among Uninsured
- FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
- PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC